Research: Epidemiology

Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes

S. V. Hope1,2, A. G. Jones2, E. Goodchild2, M. Shepherd2, R. E. J. Besser2, B. Shields2, T. McDonald2,3, B. A. Knight2 and A. Hattersley2

1Department of Geriatrics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK, 2NIHR Exeter Clinical Research Facility, Exeter, UK and 3Department of Biochemistry, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

Accepted 7 May 2013

Abstract

Aims To determine the prevalence and clinical characteristics of absolute insulin deficiency in long-standing Type 2 diabetes, using a strategy based on home urinary C-peptide creatinine ratio measurement.

Methods We assessed the urinary C-peptide creatinine ratios, from urine samples taken at home 2 h after the largest meal of the day, in 191 insulin-treated subjects with Type 2 diabetes (diagnosis age ≥45 years, no insulin in the first year). If the initial urinary C-peptide creatinine ratio was ≤0.2 nmol/mmol (representing absolute insulin deficiency), the assessment was repeated. A standardized mixed-meal tolerance test with 90-min stimulated serum C-peptide measurement was performed in nine subjects with a urinary C-peptide creatinine ratio ≤0.2 nmol/mmol (and in nine controls with a urinary C-peptide creatinine ratio >0.2 nmol/mmol) to confirm absolute insulin deficiency.

Results A total of 2.7% of participants had absolute insulin deficiency confirmed by a mixed-meal tolerance test. They were identified initially using urinary C-peptide creatinine ratio: 11/191 subjects (5.8%) had two consistent urinary C-peptide creatinine ratios ≤0.2 nmol/mmol; 9 of these 11 subjects completed a mixed-meal tolerance test and had a median stimulated serum C-peptide of 0.18 nmol/l. Five of these 9 had stimulated serum C-peptide <0.2 nmol/l and 9/9 subjects with urinary C-peptide creatinine ratio >0.2 had endogenous insulin secretion confirmed by the mixed-meal tolerance test. Compared with subjects with a urinary C-peptide creatinine ratio >0.2 nmol/mmol, those with confirmed absolute insulin deficiency had a shorter time to insulin treatment (median 2.5 vs. 6 years, P=0.005) and lower BMI (25.1 vs. 29.1 kg/m2, P=0.04). Two out of the five patients with absolute insulin deficiency were glutamic acid decarboxylase autoantibody-positive.

Conclusions Absolute insulin deficiency may occur in long-standing Type 2 diabetes, and cannot be reliably predicted by clinical features or autoantibodies. Absolute insulin deficiency in Type 2 diabetes may increase the risk of hypoglycaemia and ketoacidosis, as in Type 1 diabetes. Its recognition should help guide treatment, education and management. The urinary C-peptide creatinine ratio is a practical non-invasive method to aid detection of absolute insulin deficiency, with a urinary C-peptide creatinine ratio >0.2 nmol/mmol being a reliable indicator of retained endogenous insulin secretion.

Diabet. Med. 30, 1342–1348 (2013)

Introduction

Most older patients with diabetes have Type 2 diabetes, which is typically a disease where endogenous insulin persists. Progressive β-cell dysfunction occurs in Type 2 diabetes [1–4], but it is unclear if this leads to absolute insulin deficiency. By contrast, in Type 1 diabetes absolute insulin deficiency is usual outside the initial ‘honeymoon period’, the period soon after diagnosis when some residual β-cell function may persist [5].

Some patients may present clinically later in life as having Type 2 diabetes, but have the autoimmune destructive process as seen in Type 1 diabetes. These patients can be recognised by pancreatic autoantibodies, known as latent autoimmune diabetes of adulthood (LADA) [6]. People with LADA may develop absolute insulin deficiency [7–10]. In practice, however, autoantibody levels are rarely measured in
patients presenting with adult-onset diabetes: a clinical
diagnosis of Type 2 diabetes is usually made and seldom
revisited, and so later subsequent development of absolute
insulin deficiency is rarely suspected or tested for.

Absolute insulin deficiency in patients with Type 2
diabetes is likely to carry similar risks to those associated
with Type 1 diabetes, such as fluctuant blood glucose levels,
high hypoglycaemia risk and diabetic ketoacidosis [11]. The
patient with Type 2 diabetes, however, is unlikely to be
offered a similar level of education to deal adequately with
these, such as the Dose Adjustment for Normal Eating
(DAFNE) programme [12]. Frail older people, in particular,
may be ill-equipped to cope with such complications, with
less functional reserve both physically and cognitively, and in
terms of their social support. The development of absolute
insulin deficiency in Type 2 diabetes will alter treatment: oral
hypoglycaemic agents (especially sulphonylureas) will not be
effective, the newer agents, e.g. glucagon-like peptide (GLP)-
1 receptor analogues and dipeptidyl peptidase (DPP)4
inhibitors, are not suitable, and the most appropriate insulin
regimen may be basal-bolus rather than background long-
acting insulin. With an estimated 870 000 people with
insulin-treated Type 2 diabetes in the UK, the development
of absolute insulin deficiency in even a small proportion
could have significant impact on both individuals and
society.

Endogenous insulin levels are rarely measured in routine
clinical practice, even in secondary care, owing to practical
limitations, including the need for rapid laboratory analysis
of blood tests. The majority of patients with Type 2 diabetes
are cared for in primary care where this is even less practical.
Recently, a simple urine test, the urinary C-peptide creatinine
ratio (UCPCR) [13], has been shown both in Type 1 diabetes
and Type 2 diabetes, to be excellently correlated with the
‘gold standard’ measure of endogenous insulin secretion,
the formal mixed-meal tolerance test (MMTT), and a sensitive
and specific test for absolute insulin deficiency [5,14]. The
UCPCR test has the advantages of being widely available,
and stable at room temperature for 3 days, so offering the
potential for widespread non-invasive testing which may be
particularly useful for a more frail, older population. The
aim of the present study was to use the UCPCR to test for
absolute insulin deficiency in older people with insulin-
treated Type 2 diabetes.

Methods

Subjects

A total of 191 insulin-treated subjects with Type 2 diabetes
(clinical diagnosis of Type 2 diabetes, diagnosis at ≥ 45 years
of age, insulin treatment not started within 1 year of
diagnosis) were recruited from primary care at the time of
their routine retinal screening appointment, and written
consent was obtained for participation in the study. Baseline
data collected included duration of diabetes, current treat-
ment, BMI and most recent HbA1c concentration.

Urine collection and analysis

Participants were asked to provide an initial urine sample,
collected at home, 2 h after their largest meal of the day. The
urine sample was collected in a standard mid-stream urine
boric acid-containing specimen pot, and returned by post to
the routine pathology laboratories for UCPCR analysis.
UCPCR ≤ 0.2 nmol/mmol is equivalent to a stimulated
serum C-peptide (sSCP) of 0.2 nmol/l in an MMTT [15,16],
representing an absence of clinically significant insulin
secretion [11]. This level is associated with unstable glyca-
emia, increased risk of hypoglycaemia and microvascular
complications (as well as absolute insulin requirement) in
Type 1 diabetes [11,16].

All patients identified as insulin-deficient were asked to
provide a repeat sample to confirm their initial result, as
were a random group of those with a UCPCR >0.2 nmol/
mmol.

Mixed-meal tolerance test

In those patients with consistent UCPCR results ≤0.2 nmol/
mmol, we performed a formal MMTT with their insulin
excluded, to confirm the absolute insulin deficiency [5]. A
comparison group of age-matched participants with
UCPCR >0.2 nmol/mmol also underwent the standardized
MMTT [17]. In brief, subjects fasted from midnight, and
omitted their morning medications including insulin. Fasting
serum and urine samples were taken before participants
consumed 6 ml/kg Ensure Plus HP (Abbott Laboratories,
Abbott Park, IL, USA). A blood sample for sSCP was taken
90 min later, and a urine sample for UCPCR at 2 h. As
above, a sSCP concentration of <0.2 nmol/l was used to
represent absolute insulin deficiency [5,18].

Sample analysis

Urine and serum samples were analysed for C-peptide using
an electrochemiluminescence immunnoassay (intra-assay coe-
ficient of variation <3.3%; interassay coefficient of variation
<4.5%) on a Roche Diagnostics E170 analyser (Roche,
Mannheim, Germany) by the biochemistry department at the
Royal Devon and Exeter NHS Foundation Trust. Urine
creatinine was analysed on the Roche P800 platform using
creatinine Jaffé reagent (standardized against isotope dilution
mass spectrometry) to obtain a urinary C-peptide creatinine
ratio. Blood samples for all patients completing the MMTT
were analysed for glutamic acid decarboxylase (GAD)65 and
islet antigen 2 (IA2) autoantibodies, using the Biokit auto-
ated Elisa System (BEST 2000; Biokit, Barcelona, Spain)
following the manufacturer’s instructions. The cut-offs used
were those based on the 99th centile for 500 individuals.
without diabetes; for GAD65 the reference-positive value was >64 units/ml, for IA2 the reference-positive value was >15 units/ml.

Data analysis

The data were not normally distributed, and so are presented as medians and interquartile ranges (IQRs). Results were analysed primarily by comparing the clinical characteristics of those with confirmed absolute insulin deficiency on MMTT and those with endogenous insulin secretion, using Mann–Whitney U- and chi-squared tests (using Predictive Analytic Software: PASW 17.0). The full group of 167 participants with an initial home UCPCR >0.2 nmol/mmol was used to represent those with significant insulin secretion, given the consistency of repeat UCPCR and MMTT results in subgroups drawn from these (see Results and Fig. 1).

Ethics approval was obtained from the Southwest Research Ethics Committee.

Results

A total of 191 participants, with a median (IQR) age 73.5 (67–78) years and of whom 37% were women, provided an initial urine sample for UCPCR measurement. They had a median (IQR) age at diagnosis of 58 (50–65) years, duration of diabetes of 13.5 (9–19) years, and BMI at recruitment of 29 (25.9–33.54) kg/m². Their median (IQR) time to insulin treatment from diagnosis was 6 (3.5–11) years.

Figure 1 shows the flow of patients through the study. Of the 191 participants screened, 24 (12.5%) had UCPCR ≤ 0.2 nmol/mmol. Of these, 21 provided a repeat sample, and 11/188 (6% of the whole cohort) had two consistent UCPCR results of ≤ 0.2 nmol/mmol.

Table 1 shows the MMTT results of the two groups selected on the basis of their UCPCR. These two groups were similar in age, duration of diabetes, time to insulin from diagnosis, and BMI. As expected the sSCP concentration was lower in those with a low UCPCR than in those with a high UCPCR (median 0.18 vs. 2.0 nmol/l, respectively, P = 0.002). Five of the nine participants with a low UCPCR had a sSCP of <0.2 nmol/l, representing absolute insulin deficiency [18], in contrast to none with a high UCPCR had a sSCP <0.2 nmol/l. This suggests a minimum prevalence of absolute insulin deficiency in insulin-treated Type 2 diabetes of 3% [5/186, excluding the five subjects who were unable to provide repeat urine samples or participate in the MMTT (Fig. 1)].

Notably, the UCPCR results obtained in both groups were substantially higher after the MMTT than after the home
meal. For those four patients with two home UCPCRs $\leq 0.2$ nmol/mmol but an sSCP $>0.2$ nmol/l, the post-MMTT UCPCR results were also $>0.2$ nmol/mmol. This suggests the MMTT provided more $\beta$-cell stimulation than did the meals consumed at home.

The five patients with confirmed absolute deficiency on MMTT had a lower BMI (BMI 25.1 vs. 29.1 kg/m², $P=0.04$), and commenced insulin treatment more rapidly after diagnosis (2.5 vs. 6 years, $P=0.005$), although there was substantial overlap for both these measures between those with ($n=5$) and without ($n=167$) absolute insulin deficiency. There was no difference in age of diagnosis, duration of diabetes, glycaemic control or insulin dose (Table 2).

Two of the five participants with absolute insulin deficiency were GAD-positive (titre in both $>2000$ units/ml); one of these was also IA2 positive (titre 74.9 units/ml). In addition, one patient who had two low UCPCR measurements from home but an sSCP of 0.37 nmol/l was GAD-positive (titre $>2000$ units/ml). None of the nine participants from the comparison MMTT group, i.e. with home UCPCR demonstrating residual endogenous insulin secretion and confirmed on MMTT, were positive for GAD or IA2 antibodies.

Notably, only two of the five participants with absolute insulin deficiency were on a basal-bolus regimen, and two were treated with oral agents in combination with insulin.

### Discussion

A total of 2.7% of insulin-treated patients with a clinical diagnosis of Type 2 diabetes in the present study were found to have absolute insulin deficiency. Patients who may have had absolute insulin deficiency were detected using the simple non-invasive testing method, the UCPCR, and a MMTT was used to confirm findings. These patients cannot be solely identified on the basis of clinical characteristics, or by testing of GAD antibodies.

### Table 1

|                         | UCPCR $\leq0.2$ nmol/mmol | UCPCR $>0.2$ nmol/mmol | $P$   |
|-------------------------|----------------------------|-------------------------|-------|
| UCPCR (home), nmol/mmol | $<0.02$                   | 1.7                     | $<0.001$ |
|                         | $<0.02$–0.2               | 1.7                     | $<0.001$ |
| UCPCR (MMTT), nmol/mmol | 0.07                      | 2.6                     | 0.001 |
|                         | $<0.02$–0.7               | 2.6                     | 0.001 |
| fSCP, nmol/l            | 0.13                      | 0.39                    | 0.003 |
|                         | (0.08–0.35)               | (0.45–0.88)             |       |
| sSCP, nmol/l            | 0.18                      | 2.0                     | 0.002 |
|                         | (0.08–0.64)               | (1.53–2.52)             |       |

Data are shown as median values (interquartile range). UCPCR, urinary C-peptide creatinine ratio; MMTT, mixed-meal tolerance test; fSCP, fasting serum C-peptide; sSCP, stimulated serum C-peptide.

### Table 2

|                          | Absolute insulin deficiency | Endogenous insulin secretion | $P$   |
|--------------------------|----------------------------|----------------------------|-------|
| $n$                      | 5                          | 167                        |       |
| Age at diagnosis, years  | 63 (54–72)                 | 58 (50–66)                 | 0.28  |
| Duration of diabetes, years | 12 (9.5–19.5)             | 13 (9–17)                  | 0.87  |
| BMI, kg/m²               | 25.1 (22.8–28.8)           | 29.1 (26.3–33.6)           | 0.04  |
| HbA1c, mmol/mol          | 72 (57–85)                 | 62 (55–69)                 | 0.24  |
| HbA1c,%                  | 8.7 (7.4–9.9)              | 7.8 (7.2–8.5)              | 0.005 |
| Time to insulin from diagnosis, years | 2.5 (1.5–3) | 6 (3–10.75) |       |
| Insulin/kg/24 h, units/kg/24 h | 0.72 (0.54–0.88) | 0.51 (0.31–0.84) | 0.26  |
| No. of subjects on oral hypo-glycaemic agent, in addition to insulin (%)† | 2/5 (40) | 11/167 (69) | 0.17  |
| No. of subjects on basal-bolus regime (%)† | 2/5 (40) | 19/167 (11) | 0.05  |

Data shown as medians (interquartile range). *Chi-squared tests; all others Mann-Whitney U-test. †Basal-bolus regime: four or five injections of insulin a day.

### Prevalence and aetiology of absolute insulin deficiency in Type 2 diabetes

Our prevalence of absolute insulin deficiency of 2.7% (5/186) is similar to the 2.3% (3/133) found at 10 years from diagnosis in an observational study by Niskanen et al. [7]. This looked at adult patients over the age of 45 years with new-onset non-insulin-dependent diabetes, and measured sSCP and GAD titres at 0, 5 and 10 years. By including only insulin-treated patients in our study, one might have expected a more insulin-deficient group and hence a comparatively higher proportion of patients with absolute insulin deficiency than in the study by Niskanen et al. The aim for tighter glycaemic control (and hence earlier initiation of insulin) in the post-Diabetes Control and Complications Trial/United Kingdom Prospective Diabetes Study era may provide an explanation for why this was not seen. Additionally, the 2.7% prevalence in our study population is a minimum: there were five additional participants with an initial UCPCR suggestive of absolute insulin deficiency who were either uncontactable or unable to undergo a MMTT (Fig. 1). If all these participants had confirmed sSCP $<0.2$ nmol/l, the prevalence would have risen to 5.2% (10/191).
In subjects with high titres of GAD antibodies and reasonably long diabetes duration (10–12 years), prospective longitudinal studies have shown that many (but not all) develop absolute insulin deficiency [7,9]. When combined with the clinical features of adult-onset diabetes not immediately requiring insulin treatment, the presence of pancreatic autoantibodies is known as LADA [7,9,10]. Two of the five participants with absolute insulin deficiency in our study fit these criteria, having high GAD titres (>2000 units/ml, reference value >64 units/ml); however, with three participants with a confirmed absolute insulin deficiency not exhibiting GAD antibodies, it suggests that the presence of these antibodies is not a sensitive test for detecting the development of absolute insulin deficiency in those with long-standing diabetes.

Our study has hence identified three people with apparent non-autoimmune Type 2 diabetes and confirmed absolute insulin deficiency. Of the three patients developing absolute insulin deficiency in the study by Niskanen et al. [7], one was GAD-antibody-negative. This was the only other case we found in the literature of absolute insulin deficiency confirmed using sSCP in non-autoimmune Type 2 diabetes [7]. It is possible that the cross-sectional measurement of pancreatic autoantibodies in our study may have missed some patients who were antibody-positive at an earlier stage, but lost this positivity over time; however, numerous studies have found that high GAD titres persist [7,9,19,20]. The cross-sectional design of the present study meant we were able to look a wide range of durations of diabetes, longer than those looked at before in Type 2 diabetes, and this may help explain why we have detected absolute insulin deficiency where others have not. No previous studies we have found were designed to look for absolute insulin deficiency in Type 2 diabetes; the majority have looked at the significance of GAD antibodies on the deterioration in β-cell function over time.

Urinary C-peptide creatinine ratio testing

The urinary C-peptide creatinine ratio was used in this study as a practical test in a large number of individuals, and was able to detect patients at risk of absolute insulin deficiency. The gold standard MMTT was used to confirm findings. Those with evidence of endogenous insulin secretion on an initial UCPCR test had consistent results, both on repeat UCPCR and on MMTT. As would be expected by regression to the mean when selecting a low cut-off, those with an initial low UCPCR suggesting absolute insulin deficiency had a tendency to higher results upon repeat testing, taking some above the designated 0.2 nmol/mmol threshold. In addition, some practical issues were identified which may have led to erroneously low UCPCR results on initial testing: these included patients tipping out the boric acid preservative from the sample pots, and postal delays. Additionally, in those with low endogenous insulin levels, variation in meal stimulus may have contributed to a low UCPCR on one occasion vs. a UCPCR over the 0.2 nmol/mmol threshold on another occasion. This is supported by the finding that, in four patients, despite two home UCPCR results suggestive of absolute insulin deficiency, a higher UCPCR and measurable (though low) sSCP levels were seen under controlled MMTT conditions. This suggests the MMTT was more stimulating than the home meals of these patients and they were still able to mount an insulin response when maximally stimulated. Nevertheless, insulin secretion with their normal diet may be more clinically relevant.

The screening method did identify individuals with genuine absolute insulin deficiency. With clear instructions on how optimally to take a sample for UCPCR testing, and advice to repeat a low UCPCR in the first instance, it is a very easy and practical test which has the advantage of being widely available, avoiding the need for venepuncture, and being able to be carried out at home and posted in. Since the completion of the present study, it has been shown that the previously widely perceived practical limitations in measurement of C-peptide in blood may be to some extent overcome by using ethylenediaminetetraacetic acid (EDTA) sample tubes: these can improve the stability of C-peptide concentrations to > 24 h at room temperature (average 19.5°C) [21]. This would also make measurement of C-peptide in blood a viable test in the outpatient/primary care setting.

In the increasingly complex climate of diabetes management options, confirmation (or not) of insulin deficiency should help guide treatment, education and management decisions, which will be valuable in optimizing care for any patient, but perhaps particularly for the more frail, older patient. We would suggest that a measure of C-peptide, such as UCPCR, may have an important role when clinical features, such as marked variation in blood glucose values, suggest absolute insulin deficiency.

Clinical characteristics

In our study, those with confirmed absolute insulin deficiency had started insulin sooner after diagnosis than those with retained endogenous insulin (2.5 vs. 6 years), and had lower BMIs (25 vs. 29 kg/m²). In terms of other easily available and measurable baseline patient characteristics, there was little else to distinguish them.

Although two of the five patients with confirmed absolute insulin deficiency were on basal-bolus regimens, the three others, and several of those with low endogenous insulin levels, were on unusual regimens more suited to patients with endogenous insulin secretion. Two of the five were still on oral hypoglycaemic agents, and none had had any training, such as the DAFNE course [12], to help them understand and manage their diabetes better.

Theoretically despite a clinical diagnosis of Type 2 diabetes, patients with absolute insulin deficiency may be at risk of the complications seen in Type 1 diabetes. This was reflected in all of the patients with absolute insulin deficiency
– and those with low endogenous insulin levels - reporting difficulty in managing their blood glucose levels owing to seemingly unpredictable fluctuations in blood glucose levels, and one patient having had an episode of ketoacidosis.

Implications for clinical practice

Identification of absolute insulin deficiency in patients with a clinical diagnosis of Type 2 diabetes may enable optimization of their treatment such as basal-bolus regimens, management and education such as DAFNE courses [12], and recognition of potential complications such as higher risks of hypoglycaemia or ketoacidosis. All these have not been traditional considerations in many patients with Type 2 diabetes, and recognition should help improve the quality of life of these individuals.

The UCPCR is a practical and useful test to detect absolute insulin deficiency in Type 2 diabetes and should be used in individuals with Type 2 diabetes developing ketoacidosis, severe hypoglycaemia or having a large fluctuation in blood glucose values, to help inform optimum diagnosis and/or management. A UCPCR suggestive of endogenous insulin production is reliable, and in this clinical context may suggest other explanations for the clinical features (such as compliance). A low UCPCR suggestive of insulin deficiency should be repeated in the first instance, but may help guide management and education as described above.

Conclusion

In conclusion, we have shown that absolute insulin deficiency is present in 3% of insulin-treated subjects with Type 2 diabetes and may be detected using UCPCR. Clinical features such as GAD antibodies, starting insulin sooner after diagnosis, and having a lower BMI are pointers to help recognize those at risk, but are not diagnostic. Those with absolute insulin deficiency are at risk of more fluctuant blood glucose levels, hypoglycaemia and ketoacidosis, which may adversely affect quality of life as well as potentially have more severe consequences, especially in the older population. Recognition of absolute insulin deficiency is thus important as it will aid the optimum management of these individuals, and the UCPCR is a useful test that can be used in general practice or in outpatients to confirm a clinical suspicion of insulin deficiency.

Funding sources

This project was supported by the Peninsula National Institute for Health Research (NIHR) Clinical Research Facility, the Department of Health, and the Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC). A.T.H. is an NIHR and a Wellcome Trust senior investigator. A.T.H., B.A.K. and B.M.S. are supported by the NIHR Exeter Clinical Research Facility. NIHR have supported S.V.H. and A.G.J. through academic clinical fellowships, and support A.G.H. through a doctoral research fellowship. R.E.J.B was supported by Diabetes UK through a doctoral research fellowship. The views given in this paper do not necessarily represent those of NIHR, the NHS or the Department of Health.

Competing interests

None declared.

Acknowledgements

We thank all the study volunteers, the retinal screening team and local general practitioner practices, and all staff at the NIHR Exeter Clinical Research Facility.

References

1 Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15: 297–303.
2 Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290–296.
3 Festa A, Williams K, D’Agostino R, Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nonobese and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114–1120.
4 Zangeneh F, Arora PS, Dyck PJ, Bekris L, Lernmark A, Achenbach SJ et al. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract 2006; 12: 388–393.
5 Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 2004; 53: 250–264.
6 Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmunity in type 2 diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–362.
7 Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18: 1557–1565.
8 Borg H, Marcus C, Sjöblad S, Fernlund P, Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000; 89: 46–51.
9 Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function and after and the diagnosis of patients with adult-onset diabetes. Diabetes 2002; 51: 1754–1762.
10 Yang L, Zhou ZG, Huang G, Ouyang LL, Li X, Yan X. Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. World J Gastroenterol 2005; 11: 2900–2903.
11 Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832–836.
12 DH and Diabetes UK. Structured Patient Education in Diabetes–
Report from the Patient Education Working Group 2005.
13 McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB,
Hattersley AT. Stability and reproducibility of a single-sample
urinary C-peptide/creatinine ratio and its correlation with 24-h
urinary C-peptide. Clinical Chem 2009; 55: 2035–2039.
14 Jones AG, Besser RE, McDonald TJ, Shields BM, Hope SV,
Bowman P et al. Urine C-peptide creatinine ratio is an alternative to
stimulated serum C-peptide measurement in late-onset, insulin-
treated diabetes. Diabet Med 2011; 28: 1034–1038.
15 Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM,
Knight BA et al. Urine C-peptide creatinine ratio is a noninvasive
alternative to the mixed-meal tolerance test in children and adults
with type 1 diabetes. Diabet Care 2011; 34: 607–609.
16 Jones AG, Hattersley AT. The clinical utility of C-peptide
measurement in the care of patients with diabetes. Diabet Med
2013; 30: 803–817.
17 Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T,
Haastert B, Ludvigson J et al. Mixed-meal tolerance test versus
glucagon stimulation test for the assessment of beta-cell function in
therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966–
1971.
18 Effect of intensive therapy on residual beta-cell function in patients
with type 1 diabetes in the diabetes control and complications trial.
A randomized, controlled trial. The Diabetes Control and Compli-
cations Trial Research Group. Ann Intern Med 1998; 128:
517–523.
19 Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E,
Lampasona V et al. GAD autoantibodies and epitope reactivities
persist after diagnosis in latent autoimmune diabetes in adults but
do not predict disease progression: UKPDS 77. Diabetologia 2007;
50: 2052–2060.
20 Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A et al.
Clinical and genetic characteristics of type 2 diabetes with and
without GAD antibodies. Diabetes 1999; 48: 150–157.
21 McDonald TJ, Perry MH, Peake RW, Pullan NJ, O’Connor J,
Shields BM et al. EDTA improves stability of whole blood C-
peptide and insulin to over 24 hours at room temperature. PLoS
One 2012; 7: e42084.